Orforglipron (Foundayo) expands oral treatment options for weight management
1. Orforglipron (Foundayo) introduces a new oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken without food or timing ...
Tag: Orforglipron
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options
Geopolitical instability in the Strait of Hormuz threatens global generic drug supply Ongoing escalations in the Strait of Hormuz have ...
The Scan by 2 Minute Medicine®: Leucovorin autism update, Oura Ring FDA scrutiny, Lilly oral GLP-1 trial, and Florida vaccine mandate repeal
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Leucovorin ...
#VisualAbstract: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Orforglipron may be a safe and effective oral GLP-1 agonist for treatment of type 2 diabetes
1. Patients assigned to orforglipron experienced significant reductions in HbA1c, and body weight compared to other groups. 2. The majority ...
